MEDVi vs TrimRx: November 2026 prices compared
As of November 20, 2026, neither MEDVi nor TrimRx printed a month-to-month compounded price that applies at the maintenance dose, so this page compares what each did show and how each bills, without a price verdict.
Released · Last reviewed · how we verify
MEDVi and TrimRx, measure by measure
| Measure | MEDVi | TrimRx |
|---|---|---|
| Tirzepatide, month to month | — | — |
| Tirzepatide, lowest printed | — | — |
| Semaglutide, month to month | — | — |
| Semaglutide, lowest printed | — | — |
| Dose pricing | not confirmed | not confirmed |
| Membership or program fee | not confirmed | not confirmed |
| Computed score | 0 of 40 (position 21 of 27) | 0 of 40 (position 21 of 27) |
| FDA warning letters | 721455 (2026-02-20) | none listed |
| November 20 read | not readable Nov 20 | not readable Nov 20 |
Strengths and limitations: which fits whom
MEDVi cannot be judged on price this month because its page could not be read on November 20, 2026. TrimRx cannot be judged on price this month because its page could not be read on November 20, 2026. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.
Regulatory record
FDA’s warning-letter index lists warning letter 721455 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to MEDVi; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
Which is cheaper, MEDVi or TrimRx?
Neither printed a comparable month-to-month price on November 20, 2026, so there is no like-for-like answer this month.
Do MEDVi and TrimRx charge a membership fee?
MEDVi: not confirmed on November 20, 2026; TrimRx: not confirmed on November 20, 2026. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.
Are MEDVi and TrimRx medications FDA-approved?
Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- MEDVi pricing page (not readable on November 20, 2026)
- TrimRx pricing page (not readable on November 20, 2026)
- FDA warning letter 721455 to MEDVi (dated 2026-02-20, posted 2026-03-03)